anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
More than half of world population are H.pylori carriers. The infection is mostly acquired in childhood and persists lifelong. A notable risk factor is a lower social and economic status during childhood reflecting mostly poor hygienic standard or small and dense living area. Newly acquired infections in adulthood are a rarity. The reservoir of H. Pylori is the human stomach. H. pylori is considered to be the main pathogen involved in causing benign peptic ulcer and functional dyspepsia as well as gastric cancer. The treatment of H. Pylori infection is currently complicated by an increase in antimicrobial resistance in different parts of the world. Corresponding increase in clarithromycin as well as quinolone and metronidazole resistance poses a major clinical problem and calls for a new approach to treatment. Under such circumstances there is an emerging trend towards personalized eradication therapy. Since H. Pylori infection is an infectious disease its optimal treatment should both theoretically and practically be based on the specific characteristics of the strain and if possible the host of the infection. The aim of such an approach should be a better eradication efficacy.

Non-bismuth quadruple therapies have been proposed as potential strategies in improving the efficacy of first-line treatments. The non-bismuth quadruple therapy in its concomitant variant consists of proton pump inhibitor, amoxicillin, nitroimidazole and clarithromycin given concurrently twice daily. As a result of concurrent administration this therapy has given better results according to some studies in comparison to sequential variants. However, this therapy, as well suffers from the aforementioned increase in antibiotic resistance. Therefore, the aim of this study was to compare concomitant non-bismuth quadruple therapy with a tailored therapy based on antibiotic strain susceptibility testing assuming that eradication rate with tailored therapy will be above 90%.
If part of the experimental group, participants will have the Bioesse lavender patch placed on the chest, according to manufacturer recommendations. After the lavender patch has been in place for 5 minutes, participants will receive the same visual analogue scale (VAS) anxiety questionnaire.
The invention provides a phenylalanine-rich antibacterial peptide RFEK, and a preparation method and application thereof. The sequence of the antibacterial peptide is shown in SEQ ID No. 1. The preparation method comprises the following steps: the amino acids Phe and Arg are alternately arranged to ensure the hydrophobicity required for the antibacterial function, Glu and Lys are used for replacing Arg, so that when the peptide acts with a cell membrane, the aggregation concentration of the peptide is increased by utilizing the attraction capacity between the peptides, and a certain positive charge number required for the attraction with the bacterial cell membrane is ensured, and the antibacterial peptide is designed. The application of the antibacterial peptide in preparing medicaments for treating gram-negative bacteria infectious diseases. The preparation method is simple in technology, and antibacterial and hemolytic activity detection of the obtained antibacterial peptide shows that the antibacterial peptide has strong antibacterial activity on gram-negative strains such as escherichia coli, salmonella typhimurium, salmonella pullorum and the like, does not produce hemolysis at 128 mu M, and has a high treatment index.
The present invention relates to a preparation technology and a production method for an integrated new formulation of a bugbane rhizome and turtle shell decoction, wherein the raw materials of active ingredients comprise: 28 parts by weight of bugbane rhizome, 14 parts by weight of Chinese angelica, 14 parts by weight of bunge pricklyash peel, 28 parts by weight of licorice, 1 part by weight of turtle shell and 7 parts by weight of realgar. The production process of the integrated new formulation of bugbane rhizome and turtle shell decoction comprises the following steps of: supersonic air-jet crushing, alcohol-water extraction, ultrasonic crushing extraction, water decocting concentration, supersonic spray drying, nanometer grinding, high pressure homogenization, nano particle preparation and the like. According to the invention, the advantages, such as multi-synergism, multi-target, embodied by a nano-carrier coupling technique, are focused to be taken of. After the integrated new formulation of bugbane rhizome and turtle shell decoction is subjected to scale production, the production cost can be greatly reduced, the quality of products is greatly improved and the targeting property and the sustained and controlled release performance of the medicament are enhanced. The internal and external administration of the integrated new formulation of bugbane rhizome and turtle shell decoction can be realized simultaneously, and can be respectively taken in four time slices according to midnight-noon ebb-flow and qi and blood flowing rule of a human body. The integrated new formulation of bugbane rhizome and turtle shell decoction can be further prepared into films and transdermal agents which are respectively stuck to different parts of a human body according to the midnight-noon ebb-flow and qi and blood flowing rule of the human body and can be directly absorbed through skin.
The invention discloses a polypeptide extracted from stinging cell venom of a fire medusa. The amino acid sequence of the polypeptide is showed in the SEQ ID No.1. The invention further discloses the extraction method for the polypeptide. The extraction method comprises the steps that venom protein is extracted from the stinging cell venom of the fire medusa, then a Histrap SP strong positive ion exchange column and a Histrap Q strong anion exchange column are used sequentially to separate the polypeptide in the venom protein. The invention further discloses the application of the polypeptide in preparation of anti-nasopharynx-cancer medicine. The polypeptide can restrain the growth of a nasopharynx cancer cell strain CNE-1 and the growth of a nasopharynx cancer cell strain CNE-2 and induce the nasopharynx cancer cell to die. The extraction method for the polypeptide extracted from the stinging cell venom of the fire medusa has the advantages that the operation is simple, the separation procedures are few, the extraction method is suitable for quick separation, the separation condition is mild, and the anti-tumor activity of the obtained protein can be reserved to the largest content.
Several clinical models are being explored for use in the phase I/II evaluation of targeted therapies for breast cancer. Biological markers can be measured in early stage invasive cancers in a presurgical model involving a short term intervention. In this model, women with newly diagnosed early invasive breast cancer receive a study drug during the interval between diagnostic breast biopsy and surgical resection. Tumor tissue obtained from the biopsy and surgical specimens are used to measure pre and post treatment molecular markers, respectively. The main advantages of this model include the ability to obtain direct information on molecular response in tumor tissue and elucidate drug mechanisms of action, the large patient population to draw from with early stage breast cancer, and the lack of unnecessary invasive procedures.

We plan to conduct a pilot study of 10 postmenopausal women with newly diagnosed estrogen receptor (ER) positive invasive or non invasive breast cancer who will receive oral anastrozole 1mg daily for two weeks in the interval between diagnostic breast biopsy and definitive breast surgery. Patients will be identified by the breast surgeon or mammographer performing the breast biopsy. Patients with histologically confirmed ER+ invasive or non invasive breast cancer will be recruited by the medical oncologist and will start anastrozole two weeks prior to their scheduled surgery. The primary objective of this study is to demonstrate the feasibility of this presurgical model for evaluating targeted therapies for breast cancer. Secondary endpoints include changes in tissue levels of the proliferation marker Ki67 and proteins involved in PI3K/AKT signaling.
The present invention relates to the field of biotechnology. Provided are an mTOR inhibitor and the use thereof. The mTOR inhibitor is obtained by means of mutating aspartic acids at positions 14, 17 and 18 in 30 amino acids at the C terminal of an ATP6AP1 protein into alanines, and the sequence of the 30 amino acids is as shown in SEQ ID NO: 1. By means of a new proximity labeling and screening method, a C-terminal fragment (C tail) of an ATP6AP1 protein is found as a guanylate exchange factor (GEF) of Rheb which can activate Rheb. On this basis, aspartic acids at positions 14, 17 and 18 in 30 amino acids at the C-terminal are all mutated into alanines, so as to obtain a new mTOR inhibitor. The mTOR inhibitor can bind to and block the inhibition of Rheb by means of endogenous ATP6AP1, thereby inhibiting the mTORC1 signaling pathway.
NEW MATERIAL:A compound expressed by the formula (R is undecyloyl, stearoyl, oleoyl, linoleoyl or linolenoyl). EXAMPLE:N-Undecyloyl dopamine. USE:A blood platelet aggregation-inhibiting agent and 5-lipoxygenase inhibitor. Useful for remedy for cerebral infarction, cerebral thrombosis, arteriosclerosis, stenocardia, bronchial asthma and allergic disorder. Low in toxicity and high in safety. PREPARATION:A fatty acid carboxylic acid expressed by the formula RCOOH is reacted with dopamine hydrochloride in a solvent such as THF, etc., in the presence of a base (e.g. triethyl amine) and a peptide synthetic reagent (e.g. isobutyl chlorocarbonate) at 0 deg.C - room temperature to provide a compound expressed by the formula.
All participants receive a one time, $10 payment for attending the first exercise class of the 12 week session. Participants in the 'Lottery Insurance' arm receive a lottery ticket valued at $20 for attending either a Monday or Tuesday exercise class. They have the option to insure their lottery ticket by attending a second exercise class during the week on either Wednesday or Thursday. If they do not attend the second class, they have a 90% chance of winning the weekly lottery. This sequence is repeated each week over the 12 week exercise session.
A cerebrospinal fluid (CSF) leak developed in a 14-year-old girl and a 12-year-old boy following a diagnostic lumbar puncture. Two days and sixteen years later, respectively, paraplegia developed due to a functional disorder. Imaging revealed an extensive extradural CSF collection in both patients and digital subtraction myelography was required to pinpoint the exact site of a ventral dural puncture hole where the lumbar spinal needle had gone "through and through" the dural sac. The CSF leak was complicated by cortical vein thrombosis in one patient. Both patients underwent uneventful surgical repair of the ventral dural puncture hole with prompt resolution of the paraplegia. Iatrogenic ventral CSF leaks may become exceptionally long standing and may be complicated by paraplegia on a functional basis both in the acute and chronic phases.
FIELD: medicine, pharmacy. SUBSTANCE: invention proposes aqueous solution containing erythropoietin at concentration 500-4000 IU/1 ml, dextran of molecular mass 30000-60000 Da at concentration 6-10 wt.-%, sodium citrate and citric acid to obtain isotonicity and pH value of solution 6.5-7.5. Solution can contain additionally 5 wt.-% of mannitol or glucose. Invention provides to get useful life of solution up to 2 years under storage conditions at 2-8 C. Obtained stable erythropoietin solution can be used for treatment of patients with anemia. EFFECT: enhanced efficiency. 3 cl, 2 dwg, 1 tbl, 5 ex
The invention relates to a composite material based on a two-dimensional nano carbon sheet, and preparation and application thereof, and belongs to the technical field of nano materials. Calcining the eutectic polymer in a vacuum environment to deiodinating and carbonizing the eutectic polymer to obtain lamellar carbide, crushing the lamellar carbide, adding the lamellar carbide into an aqueous solution of the amphiphilic polymer, and carrying out ultrasonic treatment to obtain the two-dimensional nano carbon sheet. Adding the two-dimensional nano carbon sheet and montmorillonite into phosphate buffer solution, and carrying out ultrasonic treatment to enable the two-dimensional nano carbon sheet and the montmorillonite to form a composite material through pi-pi stacking effect. The nanocomposite can be used for chemical kinetics treatment by converting high-level expressed hydrogen peroxide into high-activity hydroxyl free radicals in a weak acid tumor microenvironment, and is combined with photothermal treatment generated by the nanocomposite under the illumination of near infrared two regions. Furthermore, the nanocomposite material exhibits magnetic resonance imaging and photoacoustic imaging capabilities for guiding tumor therapy. The imaging and the treatment capability are combined, and an integrated treatment diagnosis platform is established for accurate medicine.
On Day 1 subjects are dosed with 100 µg of PRX-P4-003 and PK samples are drawn according to protocol, on Day 15 subjects are dosed with 40 µg of (-)-FCF. Both treatment will be administered under the fasted conditions.
Objective: To investigate dietary patterns of individuals aged ≥50 in Shanghai and analyze their association with frailty. Methods: Using data from the third wave of the Study on Global Ageing and Adult Health in Shanghai conducted between 2018 and 2019. We collected the frequency and average intake of food by the food frequency questionnaire. Factor analysis was used to extract dietary patterns, and a frailty index was constructed using the ratio of the cumulative total score of health deficits to 35 health-related variables considered. We used an ordinal multinomial logistic regression model to analyze the association between dietary patterns and frailty. Results: A total of 3 274 participants aged (67.9±9.2) years were included in the study, including 1 971 (60.2%) men and 1 303 (39.8%) women. We extracted four dietary patterns: high-protein-nuts pattern, potato-bean-vegetable-fruit pattern, poultry-meat pattern, and high-oil-salt pattern. After adjusting for confounding factors, the logistic regression analysis showed that compared with the high-oil-salt pattern, the high-protein-nuts pattern was negatively associated with the risk of higher frailty (OR=0.743, 95%CI: 0.580-0.951). We did not find an association between dietary patterns and frailty between the different gender groups. In the age group 50-64, the high-protein-nuts and potato-bean-vegetable-fruit patterns were negatively correlated with a higher degree of frailty than the high-oil-salt pattern. In the low-level physical activity group, the high-protein-nuts pattern was negatively correlated with a higher degree of frailty than the high-oil-salt pattern (OR=0.509, 95%CI: 0.361-0.720). However, we found no significant effect of the high-protein nuts pattern, potato-bean-vegetable-fruit pattern, and poultry-meat pattern on the risk of higher frailty compared to the high-oil-salt pattern in the moderate to high level of physical activity group. Conclusions: Compared to the high-oil-salt pattern, dietary patterns with a higher intake of high-protein nuts, potatoes, legumes, and fruits and vegetables might be associated with a lower risk of higher frailty in residents aged 50-64 years of age than with a high oil and salt pattern. At the same time, it may have a more significant protective effect in people with lower physical activity levels. It is suggested that a diet rich in high-protein foods, nuts, potatoes, beans, vegetables, and fruits may help reduce and delay the risk of frailty.
PURPOSE:To obtain an external preparation having excellent skin-penetrability, capable of transferring the drug component to not only corneum but also cuticle and corium and exhibiting excellent remedying effect against profound mycosis as well as latent mycosis by compounding liposome including an antimycotic agent as a main drug component. CONSTITUTION:An antimycotic agent (e.g. imidazole derivative or antibiotic substance) is dissolved in a solvent (e.g. alcohol or polyhydric alcohol). Ultrasonic vibration is applied to a mixture of the above solution, a phospholipid and water to obtain a liposome containing the antimycotic agent included in the membrane or microsome of the phospholipid. The liposome is compounded as a main drug component. The amount of the antimycotic agent included in the liposome is 0.01-10wt.%, preferably 0.1-5wt.% and the amount of the phospholipid to be used in the formation of liposome is 0.1-10 pts. per. 1 pt. of the antimycotic agent.
Doxorubicin (DOXO) induces marked cardiotoxicity, though increased oxidative stress while there are some documents related with cardioprotective effects of some antioxidants against organ-toxicity during cancer treatment. Although magnolia bark has some antioxidant-like effects, its action in DOXO-induced heart dysfunction has not be shown clearly. Therefore, here, we aimed to investigate the cardioprotective action of a magnolia bark extract with active component magnolol and honokiol complex (MAHOC; 100 mg/kg) in DOXO-treated rat hearts. One group of adult male Wistar rats was injected with DOXO (DOXO-group; a cumulative dose of 15 mg/kg in 2-week) or saline (CON-group). One group of DOXO-treated rats was administered with MAHOC before DOXO (Pre-MAHOC group; 2-week) while another group was administered with MAHOC following the 2-week DOXO (Post-MAHOC group). MAHOC administration, before or after DOXO, provided full survival of animals during 12-14 weeks, and significant recoveries in the systemic parameters of animals such as plasma levels of manganese and zinc, total oxidant and antioxidant statuses, and also systolic and diastolic blood pressures. This treatment also significantly improved heart function including recoveries in end-diastolic volume, left ventricular end-systolic volume, heart rate, cardiac output, and prolonged P-wave duration. Furthermore, the MAHOC administrations improved the structure of left ventricles such as recoveries in loss of myofibrils, degenerative nuclear changes, fragmentation of cardiomyocytes, and interstitial edema. Biochemical analysis in the heart tissues provided the important cardioprotective effect of MAHOC on the redox regulation of the heart, such as improvements in activities of glutathione peroxidase and glutathione reductase, and oxygen radical-absorbing capacity of the heart together with recoveries in other systemic parameters of animals, while all of these benefits were observed in the Pre-MAHOC treatment group, more prominently. Overall, one can point out the beneficial antioxidant effects of MAHOC in chronic heart diseases as a supporting and complementing agent to the conventional therapies.
After laparotomy and exploration of the abdominal cavity to rule out peritoneal or hepatic metastases, the initial steps of the operation were to determine if there was true arterial tumor infiltration, along the Celiac Artery, Hepatic Artery or Superior Mesenteric Artery. To clarify this, an "arteryfirst" maneuver was performed. The strategy depended on the results of preoperative imaging defining the site of the most likely tumor infiltration. The SMA was approached from a left-sided infracolic approach if tumors of the body or tail of the pancreas were suspected to infiltrate the artery from this direction or from a posterior approach in respective situations. Once the arterial level of suspected attachment/encasement was reached, a frozen section was performed to confirm or exclude viable tumor tissue at this site. In case of remaining viable tumor, most patients will not qualify for further surgical therapy at this point. In contrast, if frozen section confirms fibrous tissue without viable tumor, this offers the possibility to perform a radical but artery-sparing procedure, All other surgical steps are carried out as usual during partial pancreatoduodenectomy (PD), distal (DP) or total pancreatectomy. Anatomic TRIANGLE bordered by the SMA, CA and PV confirming the complete removal of all soft tissue usually contained within these borders.
The children in the experimental group received the conventional protocol applied to the control group. Further, they wore TheraTog orthotic undergarment with its strapping system for 8 hours daily for 12 successive weeks.
BACKGROUND: Overweight women undergoing IVF treatment have lower success rates. Letrozole, an aromatase inhibitor, has been used as an adjunct for IVF treatment, but its specific effects in overweight women have not been investigated. This study was to explore the effects of letrozole co-treatment in an antagonist protocol for overweight infertile women undergoing IVF treatment.
METHODS: This retrospective cohort study included overweight infertile women who underwent IVF/ICSI treatment and fresh embryo transfer (ET), with or without letrozole co-treatment in an antagonist protocol, from 2007 to 2021 at Shanghai Ninth People's Hospital (Shanghai, China). A total of 704 overweight infertile women were included: 585 women were in the antagonist group, and 119 women were in the letrozole co-treatment group. The primary outcome was the live birth rate after fresh ET. Propensity score-based patient-matching was employed to balance the covariates between the groups. Multivariate logistic regression analysis was also performed to estimate odds ratio (OR) and 95% confidence interval (CI) for association of letrozole co-treatment and the live birth outcome.
RESULTS: Letrozole co-treatment induced significant changes in hormonal profile on the trigger day. The letrozole group exhibited a decrease in the total number of follicles compared to the antagonist group, but a higher proportion of large follicles at oocyte retrieval (P < 0.05). The quantity and quality of embryos were comparable between the two groups (P > 0.05). The letrozole co-treatment group had a significantly higher live birth rate than the control group (38.7% vs. 22.6%, P = 0.026). With multivariate logistic regression analysis, letrozole co-treatment was associated with higher odds of live birth after adjusting for potential confounding factors (adjusted OR = 2.00, 95% CI = 1.17-3.39, P = 0.011). Letrozole presented no significant associations with obstetrical or neonatal complications (P > 0.05).
CONCLUSION: Letrozole co-treatment in an antagonist protocol may offer potential benefits for overweight infertile women undergoing IVF treatment. Further research is warranted to validate these findings and explore the broader implications for letrozole co-treatment.